ホーム › 多発性骨髄腫 › マサチューセッツ州 › Boston
Boston、MAにおける多発性骨髄腫の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する42件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
被験者募集中第3相
- Research Site, Boston
- Research Site, Boston
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Tufts Medical Center, Boston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
被験者募集中第3相
- Dana Farber / Harvard Cancer Center, Boston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
被験者募集中第4相
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- Mass General Brigham, Boston
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
被験者募集中第2相
- Beth Israel Deaconess Medical Center, Boston
ELISA in Relapsed/Refractory MM
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
被験者募集中第3相
- Boston Medical Center, Boston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
被験者募集中第1/2相
- Dana-Farber Cancer Institute /ID# 271846, Boston
Elranatamab in R/R Multiple Myeloma
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Dana Farber Cancer institution, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
被験者募集中第1相
- Massachusetts General Hospital, Boston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
被験者募集中第3相
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
被験者募集中第1/2相
- GSK Investigational Site, Boston
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
被験者募集中第1/2相
- Research Site, Boston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- Tufts Medical Center, Boston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
被験者募集中第1/2相
- Boston Medical Center, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
被験者募集中第1/2相
- Research Site, Boston
- Research Site, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Selinexor and Backbone Treatments of Multiple Myeloma Patients
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
被験者募集中第1相
- Dana Farber/Harvard Cancer Center, Boston
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
被験者募集中
- Dana-Farber Cancer Institute, Boston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
被験者募集中
- Massachusetts General Hospital Cancer Center, Boston
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
被験者募集中
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
被験者募集中第1/2相
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
被験者募集中観察研究
- Boston University Cancer Research Center, Boston
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
- Seattle, WA22件の研究
Bostonにおける他の研究
- 乳がん111件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）86件の研究
- 大腸癌63件の研究
- 転移性癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。